Lenvatinib in Second Line Endometrial Carcinoma

NCT03005015 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

NETWORK

Sponsor class

Stopped supporting company (Eisai) withdrew their interest

Conditions

Endometrial Neoplasms

Interventions

DRUG: Lenvatinib
DRUG: Doxorubicin

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC